Header Logo

Connection

Co-Authors

Back to Details
This is a "connection" page, showing publications co-authored by STEFAN OCTAVIAN CIUREA and ELIZABETH SHPALL.
STEFAN OCTAVIAN CIUREA
Connection Strength
5.339
ELIZABETH SHPALL
  1. Results of a phase I trial with Haploidentical mbIL-21 ex vivo expanded NK cells for patients with multiply relapsed and refractory AML. Am J Hematol. 2024 05; 99(5):890-899.
    View in: PubMed
    Score: 0.236
  2. Decrease post-transplant relapse using donor-derived expanded NK-cells. Leukemia. 2022 01; 36(1):155-164.
    View in: PubMed
    Score: 0.197
  3. Haploidentical transplants for patients with relapse after the first allograft. Am J Hematol. 2020 Oct; 95(10):1187-1192.
    View in: PubMed
    Score: 0.184
  4. Haploidentical transplants for patients with graft failure after the first allograft. Am J Hematol. 2020 Oct; 95(10):E267-E269.
    View in: PubMed
    Score: 0.184
  5. Novel Disease Risk Model for Patients with Acute Myeloid Leukemia Receiving Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2020 01; 26(1):197-203.
    View in: PubMed
    Score: 0.173
  6. Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biol Blood Marrow Transplant. 2019 07; 25(7):1340-1346.
    View in: PubMed
    Score: 0.166
  7. Haploidentical Transplantation for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2018 06; 24(6):1232-1236.
    View in: PubMed
    Score: 0.151
  8. Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017 10 19; 130(16):1857-1868.
    View in: PubMed
    Score: 0.150
  9. Predictive model for survival in patients with AML/MDS receiving haploidentical stem cell transplantation. Blood. 2017 06 01; 129(22):3031-3033.
    View in: PubMed
    Score: 0.146
  10. Relapse risk and survival in patients with FLT3 mutated acute myeloid leukemia undergoing stem cell transplantation. Am J Hematol. 2017 Apr; 92(4):331-337.
    View in: PubMed
    Score: 0.145
  11. Results of a 2-arm, phase 2 clinical trial using post-transplantation cyclophosphamide for the prevention of graft-versus-host disease in haploidentical donor and mismatched unrelated donor hematopoietic stem cell transplantation. Cancer. 2016 Nov 15; 122(21):3316-3326.
    View in: PubMed
    Score: 0.139
  12. Post-transplantation cyclophosphamide versus conventional graft-versus-host disease prophylaxis in mismatched unrelated donor haematopoietic cell transplantation. Br J Haematol. 2016 05; 173(3):444-55.
    View in: PubMed
    Score: 0.136
  13. Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for?Patients with Chronic Myelomonocytic Leukemia. Biol Blood Marrow Transplant. 2016 Jan; 22(1):47-53.
    View in: PubMed
    Score: 0.131
  14. Enforced fucosylation of cord blood hematopoietic cells accelerates neutrophil and platelet engraftment after transplantation. Blood. 2015 May 07; 125(19):2885-92.
    View in: PubMed
    Score: 0.127
  15. Cord-blood engraftment with ex vivo mesenchymal-cell coculture. N Engl J Med. 2012 Dec 13; 367(24):2305-15.
    View in: PubMed
    Score: 0.108
  16. Improved early outcomes using a T cell replete graft compared with T cell depleted haploidentical hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1835-44.
    View in: PubMed
    Score: 0.105
  17. Fludarabine, melphalan, thiotepa and anti-thymocyte globulin conditioning for unrelated cord blood transplant. Leuk Lymphoma. 2012 May; 53(5):901-6.
    View in: PubMed
    Score: 0.102
  18. Donor-specific anti-HLA Abs and graft failure in matched unrelated donor hematopoietic stem cell transplantation. Blood. 2011 Nov 24; 118(22):5957-64.
    View in: PubMed
    Score: 0.100
  19. Infectious complications in cord blood and T-cell depleted haploidentical stem cell transplantation. Am J Blood Res. 2011; 1(1):98-105.
    View in: PubMed
    Score: 0.098
  20. Reversible ureteral obstruction due to polyomavirus infection after percutaneous nephrostomy catheter placement. Biol Blood Marrow Transplant. 2011 Oct; 17(10):1551-5.
    View in: PubMed
    Score: 0.096
  21. Lymphocyte recovery predicts outcomes in cord blood and T cell-depleted haploidentical stem cell transplantation. Biol Blood Marrow Transplant. 2011 Aug; 17(8):1169-75.
    View in: PubMed
    Score: 0.094
  22. High risk of graft failure in patients with anti-HLA antibodies undergoing haploidentical stem-cell transplantation. Transplantation. 2009 Oct 27; 88(8):1019-24.
    View in: PubMed
    Score: 0.087
  23. Reduced-intensity conditioning using fludarabine, melphalan and thiotepa for adult patients undergoing haploidentical SCT. Bone Marrow Transplant. 2010 Mar; 45(3):429-36.
    View in: PubMed
    Score: 0.086
  24. Long-term outcomes after haploidentical stem cell transplantation for hematologic malignancies. Blood Adv. 2024 06 25; 8(12):3237-3245.
    View in: PubMed
    Score: 0.060
  25. Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis. Bone Marrow Transplant. 2024 May; 59(5):699-704.
    View in: PubMed
    Score: 0.059
  26. Eltrombopag improves platelet engraftment after haploidentical bone marrow transplantation: Results of a Phase II study. Am J Hematol. 2024 04; 99(4):562-569.
    View in: PubMed
    Score: 0.059
  27. Molecular disparity of HLA-DPB1 is associated with the development of subsequent solid cancer after allogeneic hematopoietic stem cell transplantation. Cancer. 2023 04 15; 129(8):1205-1216.
    View in: PubMed
    Score: 0.055
  28. Donor selection for KIR alloreactivity is associated with superior survival in haploidentical transplant with PTCy. Front Immunol. 2022; 13:1033871.
    View in: PubMed
    Score: 0.054
  29. SIRPa Mismatch Is Associated With Relapse Protection and Chronic Graft-Versus-Host Disease After Related Hematopoietic Stem Cell Transplantation for Lymphoid Malignancies. Front Immunol. 2022; 13:904718.
    View in: PubMed
    Score: 0.053
  30. A randomized phase III study of pretransplant conditioning for AML/MDS with fludarabine and once daily IV busulfan???clofarabine in allogeneic stem cell transplantation. Bone Marrow Transplant. 2022 08; 57(8):1295-1303.
    View in: PubMed
    Score: 0.052
  31. Refined HLA-DPB1 mismatch with molecular algorithms predicts outcomes in hematopoietic stem cell transplantation. Haematologica. 2022 04 01; 107(4):844-856.
    View in: PubMed
    Score: 0.052
  32. Bone Marrow versus Peripheral Blood Grafts for Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2021 12; 27(12):1003.e1-1003.e13.
    View in: PubMed
    Score: 0.050
  33. Mismatch in SIRPa, a regulatory protein in innate immunity, is associated with chronic GVHD in hematopoietic stem cell transplantation. Blood Adv. 2021 09 14; 5(17):3407-3417.
    View in: PubMed
    Score: 0.050
  34. Myeloablative Fractionated Busulfan With Fludarabine in Older Patients: Long Term Disease-Specific Outcomes of a Prospective Phase II Clinical Trial. Transplant Cell Ther. 2021 11; 27(11):913.e1-913.e12.
    View in: PubMed
    Score: 0.049
  35. Outcomes in patients with CRLF2 overexpressed acute lymphoblastic leukemia after allogeneic hematopoietic cell transplantation. Bone Marrow Transplant. 2021 07; 56(7):1746-1749.
    View in: PubMed
    Score: 0.048
  36. Eltrombopag for Post-Transplantation Thrombocytopenia: Results of Phase II Randomized, Double-Blind, Placebo-Controlled Trial. Transplant Cell Ther. 2021 05; 27(5):430.e1-430.e7.
    View in: PubMed
    Score: 0.048
  37. Fractionated busulfan myeloablative conditioning improves survival in older patients with acute myeloid leukemia and myelodysplastic syndrome. Cancer. 2021 05 15; 127(10):1598-1605.
    View in: PubMed
    Score: 0.048
  38. Randomized phase II trial of extracorporeal phototherapy and steroids vs. steroids alone for newly diagnosed acute GVHD. Bone Marrow Transplant. 2021 06; 56(6):1316-1324.
    View in: PubMed
    Score: 0.047
  39. Vedolizumab for Steroid Refractory Lower Gastrointestinal Tract Graft-Versus-Host Disease. Transplant Cell Ther. 2021 03; 27(3):272.e1-272.e5.
    View in: PubMed
    Score: 0.047
  40. Impact of TKIs post-allogeneic hematopoietic cell transplantation in Philadelphia chromosome-positive ALL. Blood. 2020 10 08; 136(15):1786-1789.
    View in: PubMed
    Score: 0.047
  41. Cytogenetics and Blast Count Determine Transplant Outcomes in Patients with Active Acute Myeloid Leukemia. Acta Haematol. 2021; 144(1):74-81.
    View in: PubMed
    Score: 0.046
  42. Optimizing the Conditioning Regimen for Hematopoietic Cell Transplant in Myelofibrosis: Long-Term Results of a Prospective Phase II Clinical Trial. Biol Blood Marrow Transplant. 2020 08; 26(8):1439-1445.
    View in: PubMed
    Score: 0.045
  43. Idiopathic refractory ascites after allogeneic stem cell transplantation: a previously unrecognized entity. Blood Adv. 2020 04 14; 4(7):1296-1306.
    View in: PubMed
    Score: 0.045
  44. Long-term outcomes of Sleeping Beauty-generated CD19-specific CAR T-cell therapy for relapsed-refractory B-cell lymphomas. Blood. 2020 03 12; 135(11):862-865.
    View in: PubMed
    Score: 0.045
  45. Posttransplantation cyclophosphamide improves transplantation outcomes in patients with AML/MDS who are treated with checkpoint inhibitors. Cancer. 2020 05 15; 126(10):2193-2205.
    View in: PubMed
    Score: 0.045
  46. Significance of minimal residual disease monitoring by real-time quantitative polymerase chain reaction in core binding factor acute myeloid leukemia for transplantation outcomes. Cancer. 2020 05 15; 126(10):2183-2192.
    View in: PubMed
    Score: 0.045
  47. Outcome of Multiple Myeloma with Chromosome 1q Gain and 1p Deletion after Autologous Hematopoietic Stem Cell Transplantation: Propensity Score Matched Analysis. Biol Blood Marrow Transplant. 2020 04; 26(4):665-671.
    View in: PubMed
    Score: 0.044
  48. Myeloablative conditioning using timed-sequential busulfan plus fludarabine in older patients with acute myeloid leukemia: long-term results of a prospective phase II clinical trial. Haematologica. 2019 12; 104(12):e555-e557.
    View in: PubMed
    Score: 0.042
  49. HLA-DP mismatch and CMV reactivation increase risk of aGVHD independently in recipients of allogeneic stem cell transplant. Curr Res Transl Med. 2019 05; 67(2):51-55.
    View in: PubMed
    Score: 0.041
  50. Comparison of Outcomes of Allogeneic Hematopoietic Cell Transplantation for Multiple Myeloma Using Three Different Conditioning Regimens. Biol Blood Marrow Transplant. 2019 05; 25(5):1039-1044.
    View in: PubMed
    Score: 0.041
  51. Fludarabine with a higher versus lower dose of myeloablative timed-sequential busulfan in older patients and patients with comorbidities: an open-label, non-stratified, randomised phase 2 trial. Lancet Haematol. 2018 Nov; 5(11):e532-e542.
    View in: PubMed
    Score: 0.041
  52. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018 07; 24(7):1514-1520.
    View in: PubMed
    Score: 0.039
  53. Effect of nonpermissive HLA-DPB1 mismatches after unrelated allogeneic transplantation with in vivo T-cell depletion. Blood. 2018 03 15; 131(11):1248-1257.
    View in: PubMed
    Score: 0.039
  54. Impact of Fluid Overload as New Toxicity Category on Hematopoietic Stem Cell Transplantation Outcomes. Biol Blood Marrow Transplant. 2017 Dec; 23(12):2166-2171.
    View in: PubMed
    Score: 0.038
  55. Outcome of autologous hematopoietic stem cell transplantation in refractory multiple myeloma. Cancer. 2017 Sep 15; 123(18):3568-3575.
    View in: PubMed
    Score: 0.037
  56. Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning. Cancer. 2017 Jul 15; 123(14):2661-2670.
    View in: PubMed
    Score: 0.036
  57. Long-term follow-up of patients receiving allogeneic stem cell transplant for chronic lymphocytic leukaemia: mixed T-cell chimerism is associated with high relapse risk and inferior survival. Br J Haematol. 2017 05; 177(4):567-577.
    View in: PubMed
    Score: 0.036
  58. Clofarabine Plus Busulfan is an Effective Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Lymphoblastic Leukemia: Long-Term Study Results. Biol Blood Marrow Transplant. 2017 Feb; 23(2):285-292.
    View in: PubMed
    Score: 0.035
  59. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 09 01; 126(9):3363-76.
    View in: PubMed
    Score: 0.035
  60. Haploidentical Natural Killer Cells Infused before Allogeneic Stem Cell Transplantation for Myeloid Malignancies: A Phase I Trial. Biol Blood Marrow Transplant. 2016 07; 22(7):1290-1298.
    View in: PubMed
    Score: 0.034
  61. Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3-ITD Allelic Ratio in FLT3-ITD-Positive Acute Myelogenous Leukemia. Biol Blood Marrow Transplant. 2016 07; 22(7):1218-1226.
    View in: PubMed
    Score: 0.034
  62. Pure Red Cell Aplasia in Major ABO-Mismatched Allogeneic Hematopoietic Stem Cell Transplantation Is Associated with Severe Pancytopenia. Biol Blood Marrow Transplant. 2016 May; 22(5):961-5.
    View in: PubMed
    Score: 0.034
  63. Double umbilical cord blood transplant is effective therapy for relapsed or refractory Hodgkin lymphoma. Leuk Lymphoma. 2016 07; 57(7):1607-15.
    View in: PubMed
    Score: 0.033
  64. Allogeneic stem-cell transplantation in patients with cutaneous lymphoma: updated results from a single institution. Ann Oncol. 2015 Dec; 26(12):2490-5.
    View in: PubMed
    Score: 0.033
  65. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of?Acute Myeloid Leukemia and Myelodysplastic Syndromes. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1948-54.
    View in: PubMed
    Score: 0.032
  66. Leukemia cell mobilization with G-CSF plus plerixafor during busulfan-fludarabine conditioning for allogeneic stem cell transplantation. Bone Marrow Transplant. 2015 Jul; 50(7):939-946.
    View in: PubMed
    Score: 0.032
  67. Age and Modified European LeukemiaNet Classification to Predict Transplant Outcomes: An Integrated Approach for Acute Myelogenous Leukemia Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Aug; 21(8):1405-1412.
    View in: PubMed
    Score: 0.032
  68. Phase II Trial of Graft-versus-Host Disease Prophylaxis with Post-Transplantation Cyclophosphamide after Reduced-Intensity Busulfan/Fludarabine Conditioning for Hematological Malignancies. Biol Blood Marrow Transplant. 2015 May; 21(5):906-12.
    View in: PubMed
    Score: 0.031
  69. Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors. Biol Blood Marrow Transplant. 2014 Dec; 20(12):1975-81.
    View in: PubMed
    Score: 0.031
  70. Cytogenetics, donor type, and use of hypomethylating agents in myelodysplastic syndrome with allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2014 Oct; 20(10):1618-25.
    View in: PubMed
    Score: 0.030
  71. The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):319-26.
    View in: PubMed
    Score: 0.029
  72. Hematopoietic cell transplantation-specific comorbidity index predicts inpatient mortality and survival in patients who received allogeneic transplantation admitted to the intensive care unit. J Clin Oncol. 2013 Nov 20; 31(33):4207-14.
    View in: PubMed
    Score: 0.029
  73. A randomized phase II trial of fludarabine/melphalan 100 versus fludarabine/melphalan 140 followed by allogeneic hematopoietic stem cell transplantation for patients with multiple myeloma. Biol Blood Marrow Transplant. 2013 Oct; 19(10):1453-8.
    View in: PubMed
    Score: 0.028
  74. Outcomes of adults with acute lymphoblastic leukemia relapsing after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2013 Jul; 19(7):1059-64.
    View in: PubMed
    Score: 0.028
  75. Clofarabine combined with busulfan provides excellent disease control in adult patients with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2012 Dec; 18(12):1819-26.
    View in: PubMed
    Score: 0.026
  76. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86.
    View in: PubMed
    Score: 0.026
  77. Gemcitabine, fludarabine and melphalan as a reduced-intensity conditioning regimen for allogeneic stem cell transplant in relapsed and refractory Hodgkin lymphoma: preliminary results. Leuk Lymphoma. 2012 Mar; 53(3):499-502.
    View in: PubMed
    Score: 0.025
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.